Medical Xpress August 2, 2024
A research group led by Kyoto University has produced the world’s first pluripotent stem cell-derived killer T-cell drug to treat COVID-19. The University has filed a patent application ahead of full-scale drug development.
The newly developed medicine is based on ES cell-derived killer T-cells, which are capable of targeting and killing virus-infected cells.
Clinical trials are slated to be conducted together with Fujita Health University, with the team expecting to focus on patients who are refractory to COVID-19 treatments due to immunodeficiency as a result of cancer therapy.
...Today's Sponsors
Today's Sponsor